safety

CBD News: The Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress to the Cartagena Protocol on Biosafety, following the deposit of the instrument of acceptance by Japan on 5 December 2017, will enter into force on 5 March 2018.




safety

CBD News: The Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress to the Cartagena Protocol on Biosafety enters into force today, 5 March 2018.




safety

CBD News: Fifteen years ago, the Cartagena Protocol on Biosafety to the Convention on Biological Diversity entered into force aiming to ensure the safe handling, transfer and use of living modified organisms (or LMOs) resulting from modern biotechnology.




safety

CBD Notification SCBD/CPU/DC/KG/PD/PS/88522 (2019-110): Review of post-2020 Implementation Plan and Capacity-building Action Plan (Cartagena Protocol on Biosafety)




safety

CBD News: Twenty years ago, on 29 January 2000, Parties to the Convention on Biological Diversity (CBD) adopted the Cartagena Protocol on Biosafety. The Cartagena Protocol entered into force on 11 September 2003.




safety

NYC Silkscreen Studio Swaps Fine Art Prints for Safety Signage

Gary Lichtenstein Editions has partnered with Urban Pathways to increase awareness and safety in the homeless community.




safety

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-releasing Peptide Receptor Antagonist, in GIST Patients

Introduction: Gastrin Releasing peptide receptors (GRPRs) are potential molecular imaging targets in a variety of tumors. Recently, a 68Ga-labelled antagonist to GRPRs, NeoBOMB1, was developed for PET. We report on the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) within the EU-FP7 project Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours (‘MITIGATE’) (grant agreement number 602306) in patients with oligometastatic gastrointestinal stromal tumors (GIST). Materials and Methods: The main objectives were evaluation of safety, biodistribution, dosimetry and preliminary tumor targeting of 68Ga-NeoBOMB1 in patients with advanced TKI-treated GIST using PET/CT. Six patients with histologically confirmed GIST and unresectable primary or metastases undergoing an extended protocol for detailed pharmacokinetic analysis were included. 68Ga-NeoBOMB1 was prepared using a kit procedure with a licensed 68Ge/68Ga generator. 3 MBq/kg body-weight were injected intravenously and safety parameters were assessed. PET/CT included dynamic imaging at 5 min, 11 min and 19 min as well as static imaging at 1, 2 and 3-4 h p.i. for dosimetry calculations. Venous blood samples and urine were collected for pharmacokinetics. Tumor targeting was assessed on a per-lesion and per-patient basis. Results: 68Ga-NeoBOMB1 (50 µg) was prepared with high radiochemical purity (yield >97%). Patients received 174 ± 28 MBq of the radiotracer, which was well tolerated in all patients over a follow-up period of 4 weeks. Dosimetry calculations revealed a mean adsorbed effective dose of 0.029 ± 0.06 mSv/MBq with highest organ dose to the pancreas (0.274 ± 0.099 mSv/MBq). Mean plasma half-life was 27.3 min with primarily renal clearance (mean 25.7 ± 5.4% of injected dose 4h p.i.). Plasma metabolite analyses revealed high stability, metabolites were only detected in the urine. In three patients a significant uptake with increasing maximum standard uptake values (SUVmax at 2h p.i.: 4.3 to 25.9) over time was found in tumor lesions. Conclusion: This Phase I/IIa study provides safety data for 68Ga-NeoBOMB1, a promising radiopharmaceutical for targeting GRPR-expressing tumors. Safety profiles and pharmacokinetics are suitable for PET imaging and absorbed dose estimates are comparable to other 68Ga-labelled radiopharmaceuticals used in clinical routine.




safety

Emergency departments must not return to pre-covid days of overcrowding and lack of safety, says college




safety

Emergency departments must not return to pre-covid days of overcrowding and lack of safety, says college




safety

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Robert R. Henry
Dec 1, 2015; 38:2258-2265
Special Article Collection: Insulin




safety

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

Khalid A. Jadoon
Oct 1, 2016; 39:1777-1786
Emerging Technologies and Therapeutics




safety

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda
Sep 1, 2019; 42:1724-1732
Emerging Therapies: Drugs and Regimens




safety

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

W. Timothy Garvey
May 1, 2020; 43:1085-1093
Emerging Therapies: Drugs and Regimens




safety

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

OBJECTIVE

To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.

RESEARCH DESIGN AND METHODS

This multicenter, double-blind, treat-to-target trial randomized participants to faster aspart (n = 546) or IAsp (n = 545). All available information, regardless of treatment discontinuation or use of ancillary treatment, was used for evaluation of effect.

RESULTS

Noninferiority for the change from baseline in HbA1c 16 weeks after randomization (primary end point) was confirmed for faster aspart versus IAsp (estimated treatment difference [ETD] –0.04% [95% CI –0.11; 0.03]; –0.39 mmol/mol [–1.15; 0.37]; P < 0.001). Faster aspart was superior to IAsp for change from baseline in 1-h postprandial glucose (PPG) increment using a meal test (ETD –0.40 mmol/L [–0.66; –0.14]; –7.23 mg/dL [–11.92; –2.55]; P = 0.001 for superiority). Change from baseline in self-measured 1-h PPG increment for the mean over all meals favored faster aspart (ETD –0.25 mmol/L [–0.42; –0.09]); –4.58 mg/dL [–7.59; –1.57]; P = 0.003). The overall rate of treatment-emergent severe or blood glucose (BG)–confirmed hypoglycemia was statistically significantly lower for faster aspart versus IAsp (estimated treatment ratio 0.81 [95% CI 0.68; 0.97]).

CONCLUSIONS

In combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.




safety

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

OBJECTIVE

To assess the efficacy and safety of a 1:1 fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naive Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs).

RESEARCH DESIGN AND METHODS

In this phase 3, open-label, multicenter trial, 321 patients with HbA1c≥7.5 to ≤10.0% (58–86 mmol/mol) and fasting plasma glucose (FPG) ≤13.8 mmol/L (250 mg/dL) were randomized 1:1 to iGlarLixi or Lixi for 52 weeks. The primary end point was change in HbA1c at week 26.

RESULTS

Change in HbA1c from baseline to week 26 was significantly greater with iGlarLixi (–1.58% [–17.3 mmol/mol]) than with Lixi (–0.51% [–5.6 mmol/mol]), confirming the superiority of iGlarLixi (least squares [LS] mean difference –1.07% [–11.7 mmol/mol], P < 0.0001). At week 26, significantly greater proportions of patients treated with iGlarLixi reached HbA1c <7% (53 mmol/mol) (65.2% vs. 19.4%; P < 0.0001), and FPG reductions were greater with iGlarLixi than Lixi (LS mean difference –2.29 mmol/L [–41.23 mg/dL], P < 0.0001). Incidence of documented symptomatic hypoglycemia (≤3.9 mmol/L [70 mg/dL]) was higher with iGlarLixi (13.0% vs. 2.5%) through week 26, with no severe hypoglycemic events in either group. Incidence of gastrointestinal events through week 52 was lower with iGlarLixi (36.0% vs. 50.0%), and rates of treatment-emergent adverse events were similar.

CONCLUSIONS

This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.




safety

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

OBJECTIVE

Data regarding the effects of sodium–glucose cotransporter 2 inhibitors in the elderly (age ≥65 years) and very elderly (age ≥75 years) are limited.

RESEARCH DESIGN AND METHODS

The Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 assessed cardiac and renal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. Efficacy and safety outcomes were studied within age subgroups for treatment effect and age-based treatment interaction.

RESULTS

Of the 17,160 patients, 9,253 were <65 years of age, 6,811 ≥65 to <75 years, and 1,096 ≥75 years. Dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure consistently, with a hazard ratio (HR) of 0.88 (95% CI 0.72, 1.07), 0.77 (0.63, 0.94), and 0.94 (0.65, 1.36) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.5277). Overall, dapagliflozin did not significantly decrease the rates of major adverse cardiovascular events, with HR 0.93 (95% CI 0.81, 1.08), 0.97 (0.83, 1.13), and 0.84 (0.61, 1.15) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.7352). The relative risk reduction for the secondary prespecified cardiorenal composite outcome ranged from 18% to 28% in the different age-groups with no heterogeneity. Major hypoglycemia was less frequent with dapagliflozin versus placebo, with HR 0.97 (95% CI 0.58, 1.64), 0.50 (0.29, 0.84), and 0.68 (0.29, 1.57) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.2107). Safety outcomes, including fractures, volume depletion, cancer, urinary tract infections, and amputations were balanced with dapagliflozin versus placebo, and acute kidney injury was reduced, all regardless of age. Genital infections that were serious or led to discontinuation of the study drug and diabetic ketoacidosis were uncommon, yet more frequent with dapagliflozin versus placebo, without heterogeneity (interaction P values 0.1058 and 0.8433, respectively).

CONCLUSIONS

The overall efficacy and safety of dapagliflozin are consistent regardless of age.




safety

How Technology Is Improving Safety On the Roads and Reducing Driving Anxiety

Technology has changed a number of aspects of our everyday lives and has led to increased efficiency. But when it comes to driving, has it helped or hindered the process? In this article, we will be looking into some of the ways that technology has improved safety on our roads in the last 10 years. […]




safety

Federal Appeals Court Upholds Oregon District's Pro-Transgender 'Safety Plan'

A federal appeals court rejected a multi-pronged challenge to a school district plan allowing transgender students to use restrooms and other facilities that match their gender identity.




safety

Commonwealth child safe framework / Department of the Prime Minister and Cabinet, National Office for Child Safety.

This publication outlines the Commonwealth Child Safe Framework requirements and guidance for its implementation.The primary audience for this publication is Commonwealth entities. This publication has been developed to assist entities to understand and implement the requirements of the Commonwealth Child Safe Framework.




safety

Safety in the Friendzone.




safety

Proceedings of the 2016 Australasian Road Safety Conference, September 2016, Canberra, Australia.




safety

Proceedings of the 2017 Australasian Road Safety Conference, October 2017, Perth, Australia.




safety

Proceedings of the 2018 Australasian Road Safety Conference, October 2018, Sydney, Australia.




safety

2018-21 strategic workforce plan / Australian Maritime Safety Authority.




safety

Locating and evaluating fixed safety cameras in South Australia / CN Kloeden, TJ Bailey, TP Hutchinson.

"Fixed safety cameras that detect red light running and speeding vehicles are known to be an effective method of controlling driver behaviour and producing road safety benefits. While no definitive best practice for choosing safety camera locations was found in the literature, there are a number of criteria that are frequently used and that make sense: locations with a high number of crashes (particularly injury crashes); locations with a high proportion of speeding vehicles; locations with high traffic volumes; locations with large numbers of unprotected road users (pedestrians and bicyclists); different camera types covering different areas of the road network; and deploying cameras widely throughout the road network. Evaluation of the effects of safety cameras on particular sites and as a whole can be attempted using a number of methodologies: changes in crash numbers before and after installation; changes in vehicle speeds before and after installation; and changes in offence detections from the time of installation onwards. There are limitations with each of these methodologies such that evaluating the effectiveness of an individual safety camera is often not possible. By tracking many safety camera sites for a long period of time, the effect of the safety cameras can be examined but there will always be other factors that may explain any observed changes. A true experiment could be conducted to determine safety camera effects but it would involve deliberate non-treatment of good candidate sites for many years. This study gives a reasonable set of principles for selecting safety camera sites and evaluating their effectiveness. However, the detailed processes for South Australia will depend on what data is available, the resources and funding that can be applied, and political and other considerations." -- page 3.




safety

An examination of offences at South Australian safety camera sites / CN Kloeden, TP Hutchinson.

"Fixed safety cameras that detect speeding (and in some cases red light running) are known to be a generally effective method of controlling driver behaviour and producing road safety benefits. They were first introduced in South Australia in 1988 and are now in operation at more than 150 locations around the State. Data on the speeding and red light running offences recorded at each of the sites are now publicly available. If the number of offences declines over time, this is an indication that the safety cameras are becoming increasingly effective in preventing speeding or red light running behaviour. The offence rates of the five types of safety cameras in use in South Australia were examined on a site by site basis. Safety cameras located in South Australian 50-90 km/h speed limit zones in built-up areas showed a similar overall trend in offence rates: speeding offence rates decreased rapidly during the first two to three years of operation; continued declines in speeding offence rates occurred for many years after that; and red light running offences showed general declines over time but not as consistently or to the same extent as speeding offences. Making the cameras more conspicuous from the time of installation may accelerate their positive effects. Safety cameras may also prevent vehicle speeding on high speed rural roads upon installation (this could not be measured here) but there appears to be little change in offence rates after this time. This is possibly due to the more conspicuous nature of these cameras. The tolerances applied to point to point average speed measurements appear to be the same as applied to spot speed measurements and could reasonably be reduced." -- Summary.




safety

Evaluating behaviour change communication campaigns in health and safety : a literature review / TJ Bailey [and] LN Wundersitz.




safety

Diversity and inclusion plan 2019-2022 / Australian Maritime Safety Authority.




safety

Florida High Court Approves Request for Grand Jury Probe of School Safety

The Florida supreme court has ordered a statewide grand jury with a broad mandate to investigate school safety.




safety

National transportation safety board public forum on alcohol and drug safety education.

Springfield, Virginia : National Technical Information Service, 1986.




safety

Fresh-cut fruits and vegetables : technologies and mechanisms for safety control

9780128165393 (electronic bk.)




safety

Municipality of Qikiqtarjuaq faces 5 charges under Nunavut Safety Act

The N.W.T. and Nunavut Workers’ Safety and Compensation Commission says it filed multiple charges in the Nunavut Court of Justice under the Nunavut Safety Act on May 1.



  • News/Canada/North

safety

Workshop on Internet Safety for kids with special needs

The Computer Emergency Response Team of Mauritius (CERT-MU), a division of the National Computer Board operating under the aegis of the Ministry of Technology, Communication & Innovation organised a half day workshop with the title “Internet Safety for kids with special needs” on Wednesday, 19th February 2020 at Quartier Militaire State Secondary School (Girls). The workshop was organized in collaboration with the Ministry of Education and Human Resources, Tertiary Education and Scientific Research. The objective of the workshop was to showcase existing online dangers and, at the same time, promote the responsible use of the Internet amongst kids with special needs. A presentation was delivered by the Computer Emergency Response Team of Mauritius with focus on the responsible use of the internet and underlying dangers such as Online Predators, Sexting, Sextortion and Cyberbullying. Some 20 Special Education Needs (SEN)  schools were present.




safety

CPMI and IOSCO share authorities´ experiences in cooperation to increase FMI safety and efficiency

Press release: CPMI and IOSCO share authorities´ experiences in cooperation to increase FMI safety and efficiency, 10 December 2019




safety

Union raises concerns over lack of safety inspections after Manitoba construction worker dies on the job

The union that represents thousands of Manitoba workers is asking what safety protocols were in place when a construction worker was killed after a trench wall collapsed on him earlier this week.



  • News/Canada/Manitoba

safety

FCA's Windsor Assembly Plant, Ford looking to restart this May as union works to ensure safety

As automakers look to restart the industry, union representatives are looking to ensure safety is the number one priority for workers.



  • News/Canada/Windsor

safety

Fire safety and evacuation exercise at BER postponed until summer / No effect on commissioning

In light of the regulations on hygiene and gatherings in connection with the global corona pandemic, a fire safety and evacuation exercise, which was scheduled to take place on 29 April in Terminal T1 and the BER railway station, has been postponed yest...




safety

Fewer Fights and Increased Security: What New Data Say About School Safety

Amid public concerns about school safety fueled by high-profile school shootings, new federal data show reports of student fights, bullying, and other forms of victimization have continued a decades-long trend of decline. At the same time, schools have ramped up security measures, like the use of ca




safety

Erythropoietin for Neuroprotection in Neonatal Encephalopathy: Safety and Pharmacokinetics

Infants with hypoxic-ischemic encephalopathy suffer a high rate (>40%) of death or moderate to severe disability, even after therapeutic hypothermia. High-dose erythropoietin (Epo) reduces brain injury and improves neurologic function in animal models of neonatal hypoxic-ischemic brain injury.

Multiple doses of Epo (up to 2500 U/kg intravenously) given in conjunction with hypothermia are well tolerated in newborns with HIE. Epo doses of 1000 U/kg intravenously in cooled infants produce plasma concentrations that are neuroprotective in animal studies. (Read the full article)




safety

Home Safety and Low-Income Urban Housing Quality

The effect of substandard housing on children’s risk of diseases such as asthma has been studied; little is known about how it affects child injury risk. Pediatricians actively promote injury prevention but typically without regard to housing quality.

Low-income children are likely living in substandard homes, which is significantly associated with not having working smoke alarms and safe hot water temperatures. Pediatricians can use these results to inform anticipatory guidance. (Read the full article)




safety

Differences in Quality of Care Among Non-Safety-Net, Safety-Net, and Children's Hospitals

Previous studies suggest that hospitals under the greatest financial strain may be more prone to adverse events because they have limited resources to invest in quality and safety.

The patient population served, rather than hospital category, best predicts measured quality, underscoring the need for robust risk adjustment when incentivizing quality or comparing hospitals. Thus, problems of quality may not be systemic across hospital categories. (Read the full article)




safety

Playground Safety and Quality in Chicago

Quality urban playgrounds that are accessible and safe support physical activity and decrease injury rates. Little is known about the quality and accessibility of playgrounds in Chicago public parks.

Most playgrounds in Chicago are in fair condition, yet access to quality playgrounds varies by neighborhood. Public/private collaboration can lead to improved playgrounds, and failing playgrounds can be improved with modest investment. (Read the full article)




safety

Safety and Utilization of Influenza Immunization in Children With Inflammatory Bowel Disease

Yearly influenza immunization is recommended in patients with inflammatory bowel disease (IBD). However, concern regarding vaccine-related adverse events may limit uptake, and case reports in the literature detail disease flares after immunization.

Influenza immunization rates in children with IBD are low but immunization did not result in increased outpatient visits, hospitalizations or emergency visits. Immunization was associated with fewer IBD-related visits in the post-vaccine period, which may indicate protection against IBD symptoms. (Read the full article)




safety

Randomized Controlled Trial of a Car Safety Seat Insert to Reduce Hypoxia in Term Infants

Brief periods of low oxygen saturation are common in infants while restrained in car safety seats. There is some evidence that an insert that allows the infant head to rest in a neutral position in sleep may reduce hypoxic episodes.

This randomized controlled study shows that the insert reduced numbers of obstructive apneas and the severity of desaturation events but did not significantly reduce the overall rate of moderate desaturations. (Read the full article)




safety

Safety of Medical Interventions in Children Versus Adults

Drug use in pediatrics is often based on adult efficacy data. Clinically significant discrepancies between adults and children may exist. To our knowledge, there is no large-scale evaluation of evidence comparing rates of adverse events between adults and children.

Available evidence on the comparative safety of pharmacologic interventions in adults versus children is inconclusive. In a third of meta-analyses, twofold or greater differences were identified between adults and children, and some clinically important discrepancies were also found. (Read the full article)




safety

Live Vaccine Use and Safety in DiGeorge Syndrome

Individuals with DiGeorge syndrome (DGS) have varying degrees of immunodeficiency. All are susceptible to vaccine-preventable infections with serious complications. Although live vaccines are generally contraindicated in this population, limited evidence suggests that they may be effective and safe for select individuals.

Many individuals with DGS received live vaccines despite having a known diagnosis. Adverse events following live immunizations were typically minor and self-limited, suggesting that live vaccines may be considered for patients with DGS who exhibit mild-to-moderate immunosuppression. (Read the full article)




safety

Safety of Rotavirus Vaccine in the NICU

Rotavirus vaccination is discouraged during hospitalization, given concerns regarding live-attenuated virus transmission; vaccination is recommended upon NICU discharge for eligible infants, however. Vaccination must be initiated before 104 days of age or infants become age-ineligible.

RotaTeq vaccine administered with routine 2-month vaccinations within the NICU was tolerated in recipients, with no suggestion of symptomatic nosocomial transmission to neighboring unvaccinated infants. (Read the full article)




safety

Safety and Efficacy of Filtered Sunlight in Treatment of Jaundice in African Neonates

Phototherapy effectively treats unconjugated hyperbilirubinemia. However, in resource-poor settings, functional phototherapy devices are often unavailable due to financial constraints or erratic electrical power availability.

Filtered-sunlight phototherapy could be a cost-effective option in resource-poor settings with abundant sunlight. (Read the full article)




safety

Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis

Influenza leads to respiratory deteriorations in cystic fibrosis (CF) patients. In children, live attenuated influenza virus vaccine (LAIV) is more efficacious than inactivated influenza vaccines, which could be beneficial for CF. Data on the safety of LAIV in this population are scarce.

This study assesses LAIV’s safety in patients with CF and is necessary to determine whether the anticipated benefits associated with LAIV will outweigh potential risks. This can potentially lead to a recommendation for preferential LAIV use in this population. (Read the full article)




safety

Safety and Effectiveness of Continuous Aerosolized Albuterol in the Non-Intensive Care Setting

Continuously aerosolized albuterol been shown to be safe and effective for the treatment of severe status asthmaticus in the emergency department and ICU. Little evidence supports its use in the non–intensive care setting.

With the appropriate resources and support, continuous albuterol may be administered in the non–ICU setting with a low incidence of clinical deterioration and adverse effects. Certain clinical factors may help identify which patients may benefit from higher acuity care. (Read the full article)